Literature DB >> 8142597

Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I.

M Svenson1, M B Hansen, P Heegaard, K Abell, K Bendtzen.   

Abstract

Molecules that bind recombinant interleukin 1 (rIL-1) beta and rIL-1 receptor antagonist (rIL-1ra) with high affinity were detected in sera of healthy individuals. rIL-1 beta bound with dissociation constants in the nanomolar range, and the serum binding capacity was 40-50 ng/ml. rIL-1ra bound with 30 times higher affinity, and the serum binding capacity was 0.7-1 ng/ml. Rabbit antibodies against the recombinant-derived extracellular part of human IL-1 receptor type I (rsIL-1RI) selectively inhibited the binding of 125I-rIL-1ra to the serum factor(s). Almost 70% of the high-affinity IL-1ra-binding capacity was recovered after immunosorption with these antibodies. Binding of 125I-rIL-1ra to rsIL-1RI was blocked by rIL-1 alpha and by rIL-1 beta. In contrast, the purified rIL-1ra-binding factor (IL-1raBF) failed to bind rIL-1 alpha and rIL-1 beta. Gel filtration chromatography indicated a 1:1 binding of rIL-1 beta and rIL-1ra to their respective serum factors. The apparent molecular size of both serum factors was 70-80 kDa. Using SDS-PAGE and autoradiography, IL-1raBF had a molecular size of 60 kDa. We conclude that IL-1raBF, a serum factor which selectively and with high affinity binds IL-1ra (Kd = 70 pM), is related to or identical with a soluble form of IL-1RI. If upregulated during disease, IL-1raBF may constitute yet another level of natural regulation of IL-1 bioactivities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8142597     DOI: 10.1016/1043-4666(93)90032-z

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  17 in total

1.  Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

Authors:  Wilco de Jager; Esther P A H Hoppenreijs; Nico M Wulffraat; Lucy R Wedderburn; Wietse Kuis; Berent J Prakken
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

2.  Administration of intravenous immunoglobulin (IVIG) in vivo--down-regulatory effects on the IL-1 system.

Authors:  P Aukrust; F Müller; M Svenson; I Nordøy; K Bendtzen; S S Frøland
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 3.  Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review.

Authors:  Zdravko Jotanovic; Radovan Mihelic; Branko Sestan; Zlatko Dembic
Journal:  Drugs Aging       Date:  2012-05-01       Impact factor: 3.923

4.  Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array.

Authors:  Djeneba Dabitao; Joseph B Margolick; Joseph Lopez; Jay H Bream
Journal:  J Immunol Methods       Date:  2011-07-18       Impact factor: 2.303

5.  Profile of soluble cytokine receptors in Crohn's disease.

Authors:  T Gustot; A Lemmers; E Louis; C Nicaise; E Quertinmont; J Belaiche; S Roland; A Van Gossum; J Devière; D Franchimont
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

6.  Expression of an insulin/interleukin-1 receptor antagonist hybrid gene in insulin-producing cell lines (HIT-T15 and NIT-1) confers resistance against interleukin-1-induced nitric oxide production.

Authors:  N Welsh; K Bendtzen; M Welsh
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.

Authors:  D Burger; R Chicheportiche; J G Giri; J M Dayer
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 8.  Regulation of IL-1 signaling by the decoy receptor IL-1R2.

Authors:  Thomas Schlüter; Carsten Schelmbauer; Khalad Karram; Ilgiz A Mufazalov
Journal:  J Mol Med (Berl)       Date:  2018-08-15       Impact factor: 4.599

Review 9.  The role of growth factors and cytokines during implantation: endocrine and paracrine interactions.

Authors:  Ozlem Guzeloglu-Kayisli; Umit Ali Kayisli; Hugh S Taylor
Journal:  Semin Reprod Med       Date:  2009-02-05       Impact factor: 1.303

10.  Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays.

Authors:  Wilco de Jager; Katarzyna Bourcier; Ger T Rijkers; Berent J Prakken; Vicki Seyfert-Margolis
Journal:  BMC Immunol       Date:  2009-09-28       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.